Select year
Categories

Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023

Jun 01, 2023 | Products | Corporate

Read more

Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics

May 31, 2023 | Corporate

Read more

Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer

May 24, 2023 | Products

Read more

Myriad Genetics Earns 2023 Great Place to Work Certification™

May 08, 2023 | Corporate

Read more

Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range

May 03, 2023 | Corporate | Financial

Read more

Myriad Genetics to Participate in BofA Securities Healthcare Conference

May 02, 2023 | Corporate

Read more

Myriad Genetics to Release First Quarter Financial Results on May 3, 2023

Apr 26, 2023 | Financial | Corporate

Read more

77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey

Apr 19, 2023 | Products

Read more

Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification

Apr 18, 2023 | Products

Read more

Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program

Apr 12, 2023 | Products | Corporate

Read more

Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

Mar 02, 2023 | Products | Corporate

Read more

Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC

Mar 01, 2023 | Products

Read more

Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes

Feb 28, 2023 | Financial | Corporate

Read more

Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023

Feb 22, 2023 | Financial | Corporate

Read more

Myriad Genetics to Participate in Upcoming Healthcare Conferences

Feb 09, 2023 | Financial | Corporate

Read more

Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing

Feb 07, 2023 | Products

Read more

Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

Jan 05, 2023 | Products

Read more

Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference

Jan 04, 2023 | Corporate | Financial

Read more